Zinc-alpha2-glycoprotein, dysglycaemia and insulin resistance: a systematic review and meta-analysis
| Autor: | Kamlesh Khunti, Toru Suzuki, Thomas Yates, Melanie J. Davies, Joseph Henson, Jack A. Sargeant, Kelly A. Bowden-Davies, Harriet M. Pearsey, Daniel J. Cuthbertson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Type 2 diabetes AZGP1 Overweight Article Prediabetic State 03 medical and health sciences 0302 clinical medicine Endocrinology Insulin resistance Adipokines Diabetes mellitus Internal medicine Dysglycaemia Medicine Hyperglycaemia Humans Alpha-2-glycoprotein zinc business.industry Insulin medicine.disease Diabetes Mellitus Type 2 030220 oncology & carcinogenesis Meta-analysis Female medicine.symptom business Body mass index Polycystic Ovary Syndrome |
| Zdroj: | Reviews in Endocrine & Metabolic Disorders |
| ISSN: | 1573-2606 1389-9155 |
| Popis: | To systematically review the current literature investigating associations between zinc-alpha2-glycoprotein (ZAG) and dysglycaemia (including type 2 diabetes (T2DM), poly-cystic-ovary syndrome (PCOS), pre-diabetes or insulin resistance). This included relationships between ZAG and continuous measures of insulin and glucose. Additionally, we performed a meta-analysis to estimate the extent that ZAG differs between individuals with or without dysglycaemia; whilst examining the potential influence of adiposity. A systematic search was performed on four databases for studies on circulating ZAG concentrations in adult human populations, comparing healthy controls to individuals with dysglycaemia. Key characteristics, including the mean ZAG concentrations (mg∙L−1), and any correlational statistics between ZAG and continuous measures of glucose, glycated haemoglobin (HbA1c) or insulin were extracted. Meta-analyses were performed to compare metabolically healthy controls to cases, and on studies that compared controls and cases considered overweight or obese (body mass index (BMI) ≥25 kg.m2). 1575 papers were identified and 14 studies (16 cohorts) were considered eligible for inclusion. Circulating ZAG was lower in individuals with dysglycaemia compared to metabolically healthy controls (−4.14 [−8.17, −0.11] mg.L−1; I2 = 98.5%; p n = 332), the difference in circulating ZAG was no longer significant (−0.30 [−3.67, 3.07] mg. L−1; I2 = 28.0%; p = 0.225). These data suggest that ZAG may be implicated in dysglycaemia, although there was significant heterogeneity across different studies and the mediating effect of adiposity cannot be excluded. Therefore, more research is needed before robust conclusions can be drawn. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink